# The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer

> **NCT01503697** · — · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 75 (estimated)

## Conditions studied

- Breast Cancer
- Tumor Angiogenesis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01503697
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2012-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503697, "The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01503697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*